智通财经APP讯,瑞丽医美(02135)发布公告,于2023年12月5日,公司与Youxin订立服务协议,据此,Youxin须促使完成该交易。
根据服务协议,Youxin向公司提供的该等服务包括:(a)与Suneva进行沟通及协商,并促使签订及完成供货协议;及(b)促使公司成为贝丽菲尔于中国的医疗器械注册代理人。服务费130万美元。
公告称,服务协议旨在令Youxin提供沟通及协商服务,由此降低潜在商业风险,缩短公司取得及完成供货协议及根据供货协议成为贝丽菲尔大中华区独家分销商所需的时间,从而促使公司与Suneva完成该交易。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.